Based on innovations in nanotechnology and material science space coming out of MIT's Langer laboratory, Privo Technologies is developing an entirely new class of targeted buccal delivery of chemotherapy drugs, radiation sensitizers and radiation protectors and mitigators. The firm's proprietary nano-engineered platform is designed to create robust treatments for a wide range of indications while reducing or limiting the treatments' harmful side effects. The firm deliver drugs via the mucosa with the initial focus on oral cavity mucosa offering an alternative to needle injection: reducing toxicity and allowing for higher dosing where the drugs can be most effective all of which improve patient outcomes and compliance.
